

ARTICLE

Clinicopathological Patterns and Biochemical Markers in Serum of Uterine Leiomyoma Patients



ISSN 2816-8119

Open Access

Citation

Akram, S., Akmal, A., Ahmad, S., Ahmad, H., & Roohi N. (2022). Clinicopathological patterns and biochemical markers in serum of uterine leiomyoma patients. *Albus Scientia*, 2022, Article ID e221025, 1-7.

DOI

http://doi.org/10.56512/AS .2022.2.e221025

Copyright

Copyright © 2022 [Akram et al.]. This is an open access article distributed under the terms of the **Creative Commons** Attribution 4.0 International License, (CC BY-NC) which permits reusers to distribute. remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as Attribution is given to the creator.

Competing interests

The authors have declared that no competing interests exist.

Sundas Akram¹, Amaila Akmal¹, Shaaf Ahmad², Husna Ahmad¹, & Nabila Roohi¹

¹Institute of Zoology, University of the Punjab, Quaid-i-Azam, Campus, Lahore, 54590, Pakistan ²Mayo Hospital, King Edward Medical University, Hospital Road, Lahore, 54000, Pakistan

Received: 18 Aug 2022 | Revised: 30 Sep 2022 | Accepted: 10 Oct 2022 | Published Online: 25 Oct 2022

*nabilruhi@gmail.com

Abstract

Background: Uterine fibroids (leiomyomas) are exceedingly common reproductive neoplasms with foremost public health impact. A cross-sectional study was performed to systematically investigate the marker enzymes, clinicopathological correlations, and electrolyte profile in myoma

Method: This study enrolled 44 control and 46 leiomyoma subjects, aged 21-50 years. Anthropometric parameters, detailed history of disease and clinicopathological outcomes were documented via a standardized questionnaire followed by uterine ultrasound investigation. Venous blood samples were taken for the measurement of marker enzymes and serum electrolyte concentration with commercially accessible kits

Results: In the age group between 30-40 years high incidence of myoma (43.5%) was found. Majority of fibroids were observed single (52%) and Intramural uterine fibroids were found more common type (61%) of leiomyomas. Menorrhagia was frequent clinical demonstration with 63% leiomyoma cases. In 26% myoma women positive family history of leiomyomas was also observed. A significant increase in diastolic blood pressure (DBP) and body mass index (BMI) while in parity a significant decrease was recorded in leiomyoma patients in comparison with controls. Serum electrolytes investigation revealed a substantial increase in the calcium (Ca^{2+}) as well as chloride (Cl^-) concentration and significant drop in potassium (K^+) concentration in myoma subjects when compared to the controls. While for serum sodium (Na^+) concentration, a non-significant difference was documented between comparable groups. Analysis of marker enzymes manifested a significant increase in the serum concentration of aspartate transaminase (AST), alanine transaminase (ALT) and acid phosphatase (ACP) in fibroid patients in comparison to controls whereas non-significant variations were recorded for serum alkaline phosphatase (ALP) concentration.

Conclusion: A reduced serum K^+ concentrations and raised Ca^{2+} , Cl^- and Na^+ levels in the leiomyoma patients illustrate increased estrogen concentration, that may be responsible for fibroid growth and serum concentration of AST, ACP and ALP are sustainable diagnostic markers of uterine fibroids.

Key words: ALP, ALT, AST, Calcium, Potassium, Sodium, Uterine leiomyoma

Introduction

Uterine fibroids (leiomyomas), the most common benign muscular tumors arising from the uterine wall, are characterized by low mitotic index and high production and accumulation of irregularly arranged extracellular matrix (Yafang & Nadarajah, 2022; Halder et al., 2011). Globally, these fibroids are one of the leading gynecological problems. These fibroids affect about 77% of women in reproductive period (Ciarmela et al., 2011). Pathogenesis of these fibroids is multifactorial, and the exact etiology associated with its genesis and growth is still unclear. Nonetheless, epidemiologic evidence suggests that interactions between numerous cytokines, genes, growth factors and hormones like progesterone, estrogen and corticosterone are the main factors responsible for fibroid growth (Shen et al., 2016). Uterine leiomyomas arise as a solitary benign tumor or in groups and can be submucosal (uncommon), intramural (develop in muscular uterine wall) and subserosal. Multiple clinical risk factors including parity, premeno-

pausal status, hypertension, increasing age, early age at menarche, obesity and ethnicity have been reported to be associated with its pathogenesis (Boyles et al., 2021; Noel et al., 2019; Flake et al., 2003).

Dietary minerals and lifestyle factors have a significant effect on the expansion and development of the fibroids (Szydłowska et al., 2022; Okolo, 2008). Electrolytes are chemical fundamentals that are vital for the growth and development of living organisms (Skinner, 2005; Newman & Benfield, 2002). In fibroids patients' variation in electrolytes such as calcium (Ca²⁺), sodium (Na⁺), potassium (K⁺), phosphorus (P), magnesium (Mg²⁺) and chloride (Cl⁻) occur at cellular and molecular level. Estrogen and progesterone levels increases in fibroid patients. These hormones along with some other growth factors are actually responsible for electrolytes variations especially (Na⁺, K⁺ and Cl-) in leiomyoma patients. In addition, calcium excretion through kidney decreases because of parathyroid hormone related protein (PTHrP) leading to hypercalcemia (Ke et al., 2014; Akinlua & Ojo, 2013). Pelvic pain, premature labor eventually leading to infertility, abdominal distention are common complications linked with fibroids (Giuliani,2020). Among fibroid patients' menorrhagia also prevails because of elevated blood level of chloride, sodium (Hapangama & Bulmer, 2016). Enzymatic changes inside uterine tissues also responsible for development of fibroids. For identification and management of a disease, marker enzymes are typically used. Enzymes such as aspartate aminotransferase (AST), acid phosphatase (ACP), alanine aminotransferase (ALT) and alkaline phosphatase (ALP), can be used as a tumor marker. Normal cells produce these marker enzymes in small concentration than tumor cells (Yoo et al., 2020; Ojo & Oyeyemi, 2013).

The aim of this work was to study clinicopathological patterns and to evaluate the association of marker enzymes (ACP, ALT, ALP, and AST) and serum electrolytes (Na⁺, Ca²⁺, K⁺, Cl⁻) with uterine fibroids growth and development.

Materials and Methods

A cross-sectional study was conducted on 90 participants. The objectives and benefits of the study were explained to each of the participant before obtaining any information or blood sample and a written informed consent was signed by them prior to their recruitment in the study. Premenopausal women belonging to the same age group (20-52 years) as well as socioeconomic status were considered inclusion criteria for this study. Premenopausal status was defined as, occurrence of at least one menstrual cycle in the previous 12 months.

All of the participants were grouped into Control and Leiomyoma group. Forty-six premenopausal women with symptomatic uterine leiomyoma confirmed by ultrasound diagnosis and clear adnexa were recruited in the leiomyoma group. Women were included consecutively in leiomyoma group if they were diagnosed with at least one fibroid in uterus. Forty-four healthy reproductive age female volunteers with leiomyoma free uterine morphology, non-lactating, non-pregnant and without any gynecologic symptoms and selected as reference population were included in the control group.

A standardized questionnaire was designed which included information about the age, height and weight, parity, and history of diseases of the participants. Women who were younger than

18 years old, pregnant, postmenopausal with histopathological evidence of endometriosis, adenomyosis, pelvic inflammatory disease, ovarian or cervical malignancy or any other adnexal pathology were excluded. Women with hepatic, respiratory, renal, cardiac, and endocrine disorders as well as current genital infection were also excluded from the study. Leiomyoma patient with previous history of myomectomy or hysterectomy for the surgical intervention of uterine leiomyoma were also excluded. records of fibroid patients were reviewed Medical retrospectively and clinicopathological information covering of leiomyomas, type of leiomyoma number presence/absence of menorrhagia, was abstracted from patient's medical records. Biological feature of anemia such as hemoglobin level was also recorded for each patient and Hb level was categorized according to the WHO prescribed classification as mild anemic (10.0-10.9), moderate anemic (8.1-9.9) and severe anemic (<8.00).

Body weight (kg) and height (m) were measured for the calculation of body mass index (kg/m²). Body weight was measured using digital weighing machine. During weighing, subjects were wearing light clothing. Actual body weight of the subjects was calculated by subtracting average weight of clothing. Body height was recorded by using metric scale, with the participants standing in upright position without shoes. Body weight was compared and interpreted with reference to height (m) in order to calculate body mass index (kg/m²).

After an overnight fasting, 5ml of venous blood, from all of the participants, was collected by using peripheral venous catheter. Blood samples were transferred to the for-serum collection vacutainer and allowed to clot for 30 min. After clotting, blood samples were centrifuged at 3000rpm for 10 min. Sera supernatants were separated, aliquoted and stored without the loss of activity at -81 \square C, until assayed. Serum electrolytes and marker enzymes were analyzed with the help of commercially available diagnostic kits, using clinical chemistry analyzer.

Statistical analysis

Graph pad prism (version 6.05) was used for the statistical analysis of parameters of comparable groups and unpaired Student t-test was employed for the determination of level of significance. The results were presented as Mean± SEM at 95% confidence interval (95% CI) and a p-value < 0.05 was considered statistically significant. Data obtained from questionnaire was entered, screened, and analyzed by using statistical software (SPSS, version 21) and descriptive analysis was performed using frequencies and percentages.

Results

The clinicopathological patterns of patients with uterine leiomyomas (n=46) are summarized in Table 1.

The mean weight of the leiomyoma patients was higher, whereas no significant difference in height was observed in leiomyoma versus control group. The BMI in leiomyoma group was significantly high, indicating 11% increase as compared with controls. Out of 46 women with uterine leiomyoma, 12 (26%) women were obese. Systolic blood pressure, in the current study, varied non-significantly, whereas a significant increase of 6% in diastolic blood pressure was observed in leiomyoma group in relation to controls.

Table 1 :Summary of Clinicopathological patterns of uterine leiomyomas-

Age (Years) 21-30	Chausatauistias	Function of the last				
21-30 10 21.7 31-40 18 39.1 41-50 17 37.0 >50 1 2.2 Classification of leiomyoma Intramural leiomyomas Intramural leiomyomas 28 60.9 Subserosal leiomyomas 13 28.3 Submucosal 1 2.2 leiomyomas 4 8.7 Number of leiomyomas 8.7 1 Single 24 52.2 Multiple 22 47.8 Menorrhagia 9 63.0 Absent 17 37.0 Family history of leiomyoma Present 12 26.0 Absent 34 74.0 Parity 14 30.0 Parous 32 69.0 Weight 0 26.0 Non obese 12 26.0 Non obese 12 26.0 Non obese 34 74.0 Anemia 74.0 74.0 Anemic 17 37 <th>Characteristics</th> <th>Frequency (n)</th> <th>percentage</th>	Characteristics	Frequency (n)	percentage			
31-40 18 39.1 41-50 17 37.0 >50 1 2.2 Classification of leiomyoma 1 2.2 Intramural leiomyomas 28 60.9 Subserosal leiomyomas 13 28.3 Submucosal leiomyomas 1 2.2 Mixed sites 4 8.7 Number of leiomyomas Single 24 52.2 Multiple 22 47.8 Menorrhagia Present 29 63.0 Absent 17 37.0 Family history of leiomyoma Present 12 26.0 Absent 34 74.0 Parity Nulliparous 14 30.0 Parous 32 69.0 Weight Obese 12 26.0 Non obese 34 74.0 Anemia Non anemic 29 63.0 Anemic 17 37 Types of anemia 4 24 Moderate anemia 9 53						
A1-50		-	21.7			
Solution Solution	31-40	18	39.1			
Classification of leiomyomas 28 60.9 Subserosal leiomyomas 13 28.3 Submucosal leiomyomas 1 2.2 leiomyomas 4 8.7 Number of leiomyomas 8.7 Number of leiomyomas Single 24 52.2 Multiple 22 47.8 Menorrhagia 29 63.0 Present 29 63.0 Absent 17 37.0 Family history of leiomyoma 74.0 74.0 Parity Nulliparous 14 30.0 Parous 32 69.0 Weight 0bese 12 26.0 Non obese 12 26.0 Non obese 34 74.0 Anemia Non anemic 29 63.0 Anemic 17 37 Types of anemia 4 24 Moderate anemia 9 53	41-50	17	37.0			
Intramural leiomyomas 28 60.9 Subserosal leiomyomas 13 28.3 Submucosal leiomyomas 1 2.2 Mixed sites 4 8.7 Number of leiomyomas 8.7 Number of leiomyomas Single 24 52.2 Multiple 22 47.8 Menorrhagia Present 29 63.0 Absent 17 37.0 Family history of leiomyoma Present 12 26.0 Absent 34 74.0 Parity Nulliparous 14 30.0 Parous 32 69.0 Weight Obese 12 26.0 Non obese 12 26.0 Non anemic 29 63.0 Anemia Non anemic 17 37 Types of anemia 4 24 Moderate anemia 9 53	>50	1	2.2			
Subserosal leiomyomas 13 28.3 Submucosal leiomyomas 1 2.2 Mixed sites 4 8.7 Number of leiomyomas 8.7 Number of leiomyomas Single 24 52.2 Multiple 22 47.8 Menorrhagia Present 29 63.0 Absent 17 37.0 Family history of leiomyoma Present 12 26.0 Absent 34 74.0 Parity Nulliparous 14 30.0 Parous 32 69.0 Weight Obese 12 26.0 Non obese 12 26.0 Non obese 12 26.0 Non anemic 29 63.0 Anemia Non anemic 17 37 Types of anemia Mild anemia 4 24 Moderate anemia 9 53	Classification of leiomyoma					
Submucosal leiomyomas 1 2.2 Mixed sites 4 8.7 Number of leiomyomas 52.2 47.8 Single 24 52.2 Multiple 22 47.8 Menorrhagia 74.8 74.8 Present 29 63.0 Absent 17 37.0 Family history of leiomyoma 74.0 Present 12 26.0 Absent 34 74.0 Parity 74.0 74.0 Nulliparous 14 30.0 Parous 32 69.0 Weight 0bese 12 26.0 Non obese 12 26.0 Non obese 12 26.0 Non anemic 29 63.0 Anemia 74.0 Anemic 17 37 Types of anemia 17 37 Mild anemia 4 24 Moderate anemia 9 53	Intramural leiomyomas	28	60.9			
Ieiomyomas	Subserosal leiomyomas	13	28.3			
Mixed sites 4 8.7 Number of leiomyomas 24 52.2 Single 24 52.2 Multiple 22 47.8 Menorrhagia Present 29 63.0 Absent 17 37.0 Family history of leiomyoma Present 12 26.0 Absent 34 74.0 Parity Nulliparous 14 30.0 Parous 32 69.0 Weight Obese 12 26.0 Non obese 34 74.0 Anemia Non anemic 29 63.0 Anemia 17 37 Types of anemia Mild anemia 4 24 Moderate anemia 9 53	Submucosal	1	2.2			
Number of leiomyomas Single 24 52.2 Multiple 22 47.8 Menorrhagia 29 63.0 Present 29 63.0 Absent 17 37.0 Family history of leiomyoma 2 26.0 Present 12 26.0 Absent 34 74.0 Parity 32 69.0 Weight 32 69.0 Weight 0bese 12 26.0 Non obese 34 74.0 Anemia Non anemic 29 63.0 Anemia 17 37 Types of anemia Mild anemia 4 24 Moderate anemia 9 53	leiomyomas					
Single 24 52.2 Multiple 22 47.8 Menorrhagia 29 63.0 Present 17 37.0 Family history of leiomyoma 29 63.0 Present 12 26.0 Absent 34 74.0 Parity 30.0 9 Nulliparous 14 30.0 Parous 32 69.0 Weight 0bese 12 26.0 Non obese 34 74.0 Anemia Non anemic 29 63.0 Anemic 17 37 Types of anemia Mild anemia 4 24 Moderate anemia 9 53	Mixed sites	4	8.7			
Multiple 22 47.8 Menorrhagia 29 63.0 Present 17 37.0 Family history of leiomyoma 29 63.0 Present 12 26.0 Absent 34 74.0 Parity 30.0 32 Parous 32 69.0 Weight 34 74.0 Anemia 34 74.0 Anemia 29 63.0 Anemic 17 37 Types of anemia 4 24 Moderate anemia 9 53	Number of leiomyomas					
Menorrhagia 29 63.0 Absent 17 37.0 Family history of leiomyoma 37.0 Present 12 26.0 Absent 34 74.0 Parity 30.0 32 Nulliparous 14 30.0 Parous 32 69.0 Weight 0bese 12 26.0 Non obese 34 74.0 Anemia Non anemic 29 63.0 Anemic 17 37 Types of anemia 4 24 Moderate anemia 9 53	Single	24	52.2			
Present 29 63.0 Absent 17 37.0 Family history of leiomyoma 37.0 Present 12 26.0 Absent 34 74.0 Parity 30.0 32 Nulliparous 14 30.0 Parous 32 69.0 Weight 0bese 12 26.0 Non obese 34 74.0 Anemia Non anemic 29 63.0 Anemic 17 37 Types of anemia 4 24 Moderate anemia 9 53	Multiple	22	47.8			
Absent 17 37.0 Family history of leiomyoma 26.0 Present 12 26.0 Absent 34 74.0 Parity 30.0 32 Nulliparous 14 30.0 Parous 32 69.0 Weight 0bese 12 26.0 Non obese 34 74.0 Anemia Non anemic 29 63.0 Anemic 17 37 Types of anemia 4 24 Moderate anemia 9 53	·					
Family history of leiomyoma Present 12 26.0 Absent 34 74.0 Parity 34 30.0 Parous 32 69.0 Weight 26.0 69.0 Non obese 12 26.0 Non obese 34 74.0 Anemia Non anemic 29 63.0 Anemic 17 37 Types of anemia 4 24 Moderate anemia 9 53	Present	29	63.0			
Present 12 26.0 Absent 34 74.0 Parity 34 30.0 Nulliparous 14 30.0 Parous 32 69.0 Weight 26.0 34 74.0 Anemia 74.0 37 37 Anemia 17 37 37 Types of anemia 4 24 Moderate anemia 9 53	Absent	17	37.0			
Absent 34 74.0 Parity Nulliparous 14 30.0 Parous 32 69.0 Weight Obese 12 26.0 Non obese 34 74.0 Anemia Non anemic 29 63.0 Anemic 17 37 Types of anemia Mild anemia 4 24 Moderate anemia 9 53	Family history of leiomyoma					
Parity Nulliparous 14 30.0 Parous 32 69.0 Weight 26.0 12 26.0 Non obese 34 74.0 Anemia 8 74.0 74.0 Anemia 17 37 74.0 Types of anemia 17 37 74.0 74.0 Mild anemia 4 24 74.0	Present	12	26.0			
Nulliparous 14 30.0 Parous 32 69.0 Weight 26.0 26.0 Non obese 34 74.0 Anemia 74.0 74.0 Anemia 74.0 74.0 Anemia 77.0 77.0 Types of anemia 77.0 77.0 Mild anemia 77.0 77.0 Moderate anemia 9 53.0	Absent	34	74.0			
Parous 32 69.0 Weight 26.0 Non obese 12 26.0 Non obese 34 74.0 Anemia 29 63.0 Anemic 17 37 Types of anemia 4 24 Moderate anemia 9 53	Parity					
Parous 32 69.0 Weight 26.0 Non obese 12 26.0 Non obese 34 74.0 Anemia 29 63.0 Anemic 17 37 Types of anemia 4 24 Moderate anemia 9 53	Nulliparous	14	30.0			
Obese 12 26.0 Non obese 34 74.0 Anemia Non anemic 29 63.0 Anemic 17 37 Types of anemia Mild anemia 4 24 Moderate anemia 9 53		32	69.0			
Non obese 34 74.0 Anemia 29 63.0 Anemic 17 37 Types of anemia 4 24 Moderate anemia 9 53	Weight					
Anemia 29 63.0 Anemic 17 37 Types of anemia 4 24 Moderate anemia 9 53	Obese	12	26.0			
Non anemic 29 63.0 Anemic 17 37 Types of anemia 4 24 Moderate anemia 9 53	Non obese	34	74.0			
Anemic 17 37 Types of anemia 4 24 Mild anemia 4 24 Moderate anemia 9 53						
Types of anemia Mild anemia 4 24 Moderate anemia 9 53	Non anemic	29	63.0			
Mild anemia 4 24 Moderate anemia 9 53	Anemic	17	37			
Moderate anemia 9 53	Types of anemia					
	-,,	4	24			
Severe anemia 4 24	Moderate anemia	9	53			
	Severe anemia	4	24			

The parity of leiomyoma group was significantly low as compared to controls with 25% reduction (p=0.03). Moreover, 14 (30%) leiomyoma women were found nulliparous. Serum electrolyte analysis revealed non-significant increase of 1.4% in serum sodium, a significant decrease of 18% in serum potassium, a marked increase of 9% in serum chloride and a significant elevation of 21% in serum calcium concentration in leiomyoma patients in relation to control subjects. Among marker enzymes, significant elevations in the serum levels of ALT(40%), ACP(22%) and AST (19%) were observed in leiomyoma patients in comparison with controls. However, level of ALP declined non-significantly by 11% in as comparable groups. This scatter diagram shows significant correlation between largest leiomyoma volume and AST level (Table 2.)

Age distribution frequency of fibroid patients exhibited that highest number of fibroid patients were between the age of 31-40 years with 39.1% of the leiomyoma patients, followed by age group of 41-50 years with 37% patients, followed by the age group of 21-30 years with 21.7% of the patients (Figure 1).

Among types of leiomyomas, the most frequent type was intramural (61%) followed by subserosal fibroids (28%). It was observed that incidences of mixed sites (9%) and submucosal leiomyomas (2%) were relatively low (Figure 2).

Table 2: Comparison of anthropometric parameters, age, parity, electrolyte profile and marker enzymes among control and leiomyoma groups. Values are Mean ± SEM.

Parameters	Control group	Leiomyom a group	p-value	%
	(n=44)	(n=46)	-	Difference
Weight	57.82	64.85	0.0024**	12%个
(kg)	±0.93	±2.01	0.0024	
Height (m)	1.58±0.01	1.58±0.01	0.73	0%
BMI	23.20	25.68	0.0012**	11%个
(kg/m2)	±0.27	±0.67	0.0012	
SBP	115.8	119.8	0.07	4%个
(mmHg)	±1.54	±1.62	0.07	
DBP	72.61	77.07	0.012*	6%个
(mmHg)	±1.31	±1.14	0.012	
Parity	4.00±0.26	3.00±0.38	0.03*	25%↓
Age	35.32	38.83	0.07	9%个
Age	±1.68	±1.12	0.07	
Sodium	154.8	157.1	0.64	1.48个
(mmol/L)	±3.51	±3.34	0.04	1.101
Potassium	5.50±0.20	1.10±0.25	0.0027**	20↓
(mmol/L)				
Chloride	101.7	111.3	<0.0001**	9.43↑
(mmol/L)	±1.24	±1.82	*	3.13
Calcium	4.99±0.13	6.13±0.10	<0.0001**	22.8↑
(mmol/L)		0.10000100	*	
Alkaline	228.5	204.8		_
phosphata	±10.5	±8.45	0.08	11%↓
se (U/L)	-			
Acid	4 40 . 0 07	4 70 . 0 44	0.00#	222/ 4
phosphata	1.43±0.07	1.73±0.11	0.03*	22%个
se (U/L)	25.22	20.00		
AST(U/L)	25.23	30.00	0.02*	19%个
	±1.40	±1.49		
ALT (U/L)	23.64	33.02	0.0001***	40%个
	±1.29	±1.65		




Figure 1: Frequency distribution (primary y-axis) and percentage (secondary y-axis) of the leiomyoma patients grouped according to their age. The highest frequency and percentage were record in the age group of 31-40 years, followed by age group 41-50years, followed by the age group of 21-30 years.

Regarding the number of leiomyomas, rate of occurrence of single leiomyomas was high with 52% cases, whereas 22 cases with multiple leiomyoma (48%) were identified. Among leiomyoma patients, menorrhagia was widespread with 63% cases, whereas 17 patients (37%) exhibited absence of menorrhagia. Family history of leiomyoma was found in 12 (26%) out of 46 leiomyoma women. According to the blood Hb picture, 29 patients (63%) of leiomyoma were non anemic,

whereas 17 patients (3%) were anemic. Among anemic patient 53% patients had moderate anemia in comparison to mild (24%) and severe anemia (24%) (Figure. 3).




Figure 2: Percentage distribution of different types of uterine leiomyomas. The highest percentage of 61% of intramural leiomyomas were found followed by subserosal leiomyomas 28%, whereas mixed sites and submucosal leiomyomas was relatively low.




Fig. 3: Frequency and percentage distribution of non-anemic (63%) and anemic (17%) leiomyoma patients. Among anemic patients 53% had moderate anemia whereas 24 percent patients had mild and severe anemia.

Discussion

Our results show that most common leiomyomas were found in age group 31 to 50 years. Risk of uterine fibroids increases with age that may be on the account of collective stimulating effects of progesterone and estrogen on uterine muscular tissues (Bariani et al., 2020; He et al. 2013).

In the current study no significant association was found between uterine leiomyoma risk and body height despite the positive association between plasma follicular phase estradiol level and height. As compared to the controls mean BMI of leiomyoma group was significantly higher. Obesity and increased BMI may influence the leiomyoma risk by decreasing the production of sex hormone binding globulins (SHBG) from hepatic cells which eventually leads to increased availability of

biologically active androgen as well as estrogen in obese women (Maggio et al., 2008). In obese women conversion of androgen to estrogen is also increased by more adipose tissues (Katzer et al., 2021). Moreover, obesity accompany dyslipidemia, hypertension and hyperinsulinemia stimulate uterine fibroid cells by preferentially mediating growth factors (Hoffman et al., 2021;Baird et al., 2009).

A significant increase in diastolic blood pressure was observed in leiomyoma group. Endothelial dysfunction caused by altered secretions of certain vasoactive factors may be responsible for hypertension in leiomyoma patients (Kirschen et al., 2021).

A substantial decrease of parity was found in leiomyoma patients. Nulliparity or reduced parity are most prospective factors for uterine fibroid origin. Nulliparity may contribute to this disease by increasing the stimulation of uterine smooth muscle cells via unchecked progesterone and estrogen production by an ovulatory cycle linked with them (Yang et al., 2022; Marshall et al., 2004;). Alternatively, uterine fibroids may actually contribute to nulliparity through interfering with normal process of ovum implantation and progression of pregnancy by their protrusion into the uterine cavity (Turocy, & Williams, 2022). Intramural myomas were most common in current study because these are frequently the benign tumors of muscular origin, arranged inside the uterine smooth muscle cells in concentric whorl (Sarkodie et al., 2012).

As compared to multiple fibroids single uterine leiomyomas were diagnosed in higher frequency that may be associated to racial or genetic elements (Abdullah & Gomaa, 2013). Menorrhagia was found in majority of the participants. Disturbance in normal menstrual cycle leads to the greater incidence of menorrhagia. This disturbance is caused by altered angiogenesis in the form of abnormal appearance and distribution of blood vessels in uterine fibroid tissues (Dolmans et al., 2021). In present study family history of myoma was found in 26% women. Due to genetic basis of these neoplasms, there is an association between and positive family history of fibroid and development of uterine myoma (Baird et al., 2007). A significant decrease in blood hemoglobin concentration was observed in leiomyoma group. This decrease is because of the hyper menorrhea caused by fibroids that eventually leads to the iron deficiency anemia (Collins et al., 2021).

An increase in serum sodium (Na⁺), calcium (Ca²⁺) and chloride (Cl) concentration were observed in leiomyoma patients. Though, potassium level was significantly lower in myoma group. Higher estrogen level was actually responsible for an increase in sodium concentration. Inside blood 17-β estradiol plays an essential role in sodium retention. It retains sodium either directly by stimulation of renal tubules receptors or indirectly via aldosterone (Boschitsch et al., 2010). In kidneys aldosterone receptors over simulated by elevated estrogen level which eventually enhance the physiological processes of aldosterone e.g., excretion of magnesium and potassium through urine while retention of H2O along with sodium (Armaniniet al., 2018). Additionally, estrogen stimulates potassium release directly in urine in exchange for sodium (Williams, 2005). A noteworthy increase in chloride concentration in serum of leiomyoma patients was due to the higher level of blood sodium by kidney dysfunction and estrogen (Shenget al., 2020). As compared to normal myometrial tissues uterine fibroids cells

manifest high expression of PTH-rP (parathyroid hormone related peptide) genes. This enhanced expression is responsible for an increase in serum calcium (Ca²⁺) levels in patients because PTH-rP secreted in small amounts from many cells, mostly of squamous origin, decreases calcium excretion via kidney and responsible for hypercalcemia like PTH (Lim & Oliva 2019;Truong et al., 2003).

Concerning marker enzymes, in current study a significant increase in serum acid phosphatase levels was found in women with uterine myomas compared with controls. In benign neoplasms ACP activity may be elevated because of more lysosomal participation for the implementation of apoptosis in order to degenerate these neoplasms (Atkinson, 2018;Zakeri et al., 1994).A non-significant difference was found regarding serum alkaline phosphatase levels, in current study between comparable groups. This indicates ALP as non-predictive of uterine myomas.

Moreover, Circulating ALT and AST were significantly higher in leiomyoma patients. These elevations are due to enhanced rate of aerobic glycolysis. Actually, glycolysis increases the production of alanine and glutamate that enhanced the aminotransferases activity in tumors tissues than normal tissues (Yoo et al., 2020;Chougule et al., 2008). In this study a significant correlation between the leiomyoma size and serum aspartate transaminase level was also revealed. This finding suggests that the patients with higher serum levels of aspartate transaminase (AST) tend to have larger fibroids.

Conclusion

Taken together the findings of this study, we can conclude that leiomyomas manifest variations in clinical and pathological presentations like other neoplasms with associated complications like infertility, high body mass index (BMI), anemia and menorrhagia in the reproductive women. Changes in the serum electrolyte profiles through estrogen can be related to leiomyomas developments and ACP, ALT and AST levels can be potential predictor marks for leiomyomas besides, the family history as an influencing factor for their development.

Author contributions

The authors confirm the contribution of all authors in the paper NR, SA²: study conception and design; SA¹, AA, HA: sample, data collection and analysis; SA¹, AA: interpretation of results; SA¹, AA, HA; draft manuscript preparation:SA¹, HA, NR. All authors reviewed the results and approved the final version of the manuscript.

References

Abdullah, L., & Gomaa, W. (2013). The Clinicopathological Characteristics of Uterine Leiomyomas: A Tertiary Care Centre Experience in Saudi Arabia. *Life Science Journal*, *10*(4), 3167-3171.

Akinlua, I., & Ojo, O. C. (2013). Biochemical changes in fibroid patients. *Advances in Life Science & Technology*, 13, 6-8.

Armanini, D., Sabbadin, C., Donà, G., Bordin, L., Marin, L., Andrisani, A., & Ambrosini, G. (2018). Uterine fibroids and risk of hypertension: implication of inflammation and a possible role of the renin-angiotensin-aldosterone system. *The Journal of*

Clinical Hypertension, 20(4), 727. https://doi.org/10.1111/jch.13262

Atkinson D. (2018). Hormonal Therapy Before Surgery for Uterine Fibroids. *The American Journal of Nursing*, *118*(11), 19. https://doi.org/10.1097/01.NAJ.0000547657.69144.62

Baird, D. D., Dunson, D. B., Hill, M. C., Cousins, D., & Schectman, J. M. (2007). Association of physical activity with development of uterine leiomyoma. *American Journal of Epidemiology*, 165(2), 157-163.

https://doi.org/10.1093/aje/kwj363

Baird, D. D., Travlos, G., Wilson, R., Dunson, D. B., Hill, M. C., D'Aloisio, A. A., London, S. J., & Schectman, J. M. (2009). Uterine leiomyomata in relation to insulin-like growth factor-I, insulin, and diabetes. *Epidemiology*, *20*(4), 604–610. https://doi.org/10.1097/EDE.0b013e31819d8d3f

Bariani, M. V., Rangaswamy, R., Siblini, H., Yang, Q., Al-Hendy, A., & Zota, A. R. (2020). The role of endocrine-disrupting chemicals in uterine fibroid pathogenesis. *Current Opinion in Endocrinology, Diabetes, and Obesity*, 27(6), 380. https://doi.org/10.1097%2FMED.00000000000000578

Boschitsch, E., Mayerhofer, S., & Magometschnigg, D. (2010). Hypertension in women: the role of progesterone and aldosterone. *Climacteric*, *13*(4), 307-313.

https://doi.org/10.3109/13697131003624649

Boyles, A. L., Beverly, B. E., Fenton, S. E., Jackson, C. L., Jukic, A., Sutherland, V. L., Baird, D. D., Collman, G. W., Dixon, D., Ferguson, K. K., Hall, J. E., Martin, E. M., Schug, T. T., White, A. J., & Chandler, K. J. (2021). Environmental factors involved in maternal morbidity and mortality. *Journal of Women's Health*, *30*(2), 245–252. https://doi.org/10.1089/jwh.2020.8855

Chougule, A., Hussain, S., & Agarwal, D. P. (2008). Prognostic and diagnostic value of serum pseudocholinesterase, serum aspartate transaminase, and serum alanine transaminase in malignancies treated by radiotherapy. *Journal of Cancer Research and Therapeutics*, 4(1), 21.

https://www.canceriournal.net/text.asp?2008/4/1/21/39601

Ciarmela, P., Islam, M. S., Reis, F. M., Gray, P. C., Bloise, E., Petraglia, F., Vale, W., & Castellucci, M. (2011). Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. *Human Reproduction Update*, 17(6), 772–790. https://doi.org/10.1093/humupd/dmr031

Collins, S. C., Martin, J. R., & Pal, L. (2021). Amenorrhea and Abnormal Uterine Bleeding. In *Contemporary Obstetrics and Gynecology for Developing Countries* (pp. 525-541). Springer, Cham. https://doi.org/10.1007/978-3-030-75385-6 49

Dolmans, M. M., Cacciottola, L., & Donnez, J. (2021). Conservative Management of Uterine Fibroid-Related Heavy Menstrual Bleeding and Infertility: Time for a Deeper Mechanistic Understanding and an Individualized Approach. *Journal of Clinical Medicine*, 10(19), 4389.

https://doi.org/10.3390/jcm10194389

Flake, G. P., Andersen, J., & Dixon, D. (2003). Etiology and pathogenesis of uterine leiomyomas: a review. *Environmental Health Perspectives*, *111*(8), 1037-1054. https://doi.org/10.1289/ehp.5787

Giuliani, E., As-Sanie, S., & Marsh, E. E. (2020). Epidemiology and management of uterine fibroids. *International Journal of Gynecology & Obstetrics*, *149*(1), 3-9. https://doi.org/10.1002/ijgo.13102

Halder, S. K., Goodwin, J. S., & Al-Hendy, A. (2011). 1, 25-Dihydroxyvitamin D3 reduces TGF-β3-induced fibrosis-related gene expression in human uterine leiomyoma cells. *The Journal of Clinical Endocrinology & Metabolism*, *96*(4), E754-E762. https://doi.org/10.1210/jc.2010-2131

Hapangama, D. K., & Bulmer, J. N. (2016). Pathophysiology of heavy menstrual bleeding. *Women's Health*, *12*(1), 3-13. https://doi.org/10.2217/whe.15.81

He, Y., Zeng, Q., Dong, S., Qin, L., Li, G., & Wang, P. (2013). Associations between uterine fibroids and lifestyles including diet, physical activity, and stress: a case-control study in China. *Asia Pacific Journal of Clinical Nutrition*, 22(1), 109–117. https://doi.org/10.6133/apjcn.2013.22.1.07

Hoffman, D. J., Powell, T. L., Barrett, E. S., & Hardy, D. B. (2021). Developmental origins of metabolic diseases. *Physiological Reviews*, *101*(3), 739-795.

https://doi.org/10.1152/physrev.00002.2020

Karumanchi, S. A., & Bdolah, Y. (2004). Hypoxia and sFlt-1 in preeclampsia: the "chicken-and-egg" question. *Endocrinology*, *145*(11), 4835-4837. https://doi.org/10.1210/en.2004-1028

Katzer, K., Hill, J. L., McIver, K. B., & Foster, M. T. (2021). Lipedema and the potential role of estrogen in excessive adipose tissue accumulation. *International Journal of Molecular Sciences*, 22(21), 11720.

https://doi.org/10.3390/ijms222111720

Ke, X., Cheng, Z., Qu, X., Dai, H., Zhang, W., & Chen, Z. J. (2014). High expression of calcium channel subtypes in uterine fibroid of patients. *International Journal of Clinical and Experimental Medicine*, 7(5), 1324.

Kirschen, G. W., AlAshqar, A., Miyashita-Ishiwata, M., Reschke, L., El Sabeh, M., & Borahay, M. A. (2021). Vascular biology of uterine fibroids: connecting fibroids and vascular disorders. *Reproduction*, *162*(2), R1-R18.

https://doi.org/10.1530/REP-21-0087

Lim, D., & Oliva, E. (2019). Gynecological neoplasms associated with paraneoplastic hypercalcemia. *Seminars in Diagnostic Pathology*, 36(4), 246–259. https://doi.org/10.1053/j.semdp.2019.01.003

Maggio, M., Lauretani, F., Basaria, S., Ceda, G. P., Bandinelli, S., Metter, E. J., Bos, A. J., Ruggiero, C., Ceresini, G., Paolisso, G., Artoni, A., Valenti, G., Guralnik, J. M., & Ferrucci, L. (2008). Sex hormone binding globulin levels across the adult lifespan in women--the role of body mass index and fasting insulin. *Journal of Endocrinological Investigation*, 31(7), 597–601. https://doi.org/10.1007/BF03345608

Marshall, L. M., Spiegelman, D., Manson, J. E., Goldman, M. B., Barbieri, R. L., Stampfer, M. J., Willett, W. C., & Hunter, D. J. (1998). Risk of uterine leiomyomata among premenopausal women in relation to body size and cigarette smoking. *Epidemiology*, *9*(5), 511–517. http://www.jstor.org/stable/3702527.

Newman, D. K., & Banfield, J. F. (2002). Geomicrobiology: how molecular-scale interactions underpin biogeochemical systems. *Science*, *296*(5570), 1071-1077. https://doi.org/10.1126/science.1010716

Noel, N. L., Gadson, A. K., & Hendessi, P. (2019). Uterine Fibroids, Race, Ethnicity, and Cardiovascular Outcomes. *Current Cardiovascular Risk Reports*, 13(9), 1-7. https://doi.org/10.1007/S12170-019-0622-0

Ojo, O. C., & Oyeyemi, A. O. (2013). Evaluation of marker enzymes in fibroid patients. *IOSR Journal of Environmental Science, Toxicology and Food Technology*, *5*, 29-31.

Okolo, S. (2008). Incidence, aetiology, and epidemiology of uterine fibroids. *Best practice & research Clinical Obstetrics & Gynaecology*, 22(4), 571-588.

https://doi.org/10.1016/j.bpobgyn.2008.04.002

Parker, W. H. (2007). Etiology, symptomatology, and diagnosis of uterine myomas. *Fertility & Sterility*, 87(4), 725-736. https://doi.org/10.1016/j.fertnstert.2007.01.093

Sarkodie, D., Dzefi-Tettey, K., Obeng, H., KwadwoAdjei, P., & Coleman, J. (2012). Prevalence and sonographic patterns of uterine fibroid among Ghanaian women (Uterine Fibroid-The Ghanaian situation).

Shen, Y., Wu, Y., Lu, Q., & Ren, M. (2016). Vegetarian diet and reduced uterine fibroids risk: A case–control study in Nanjing, China. *Journal of Obstetrics and Gynaecology Research*, 42(1), 87-94. https://doi.org/10.1111/jog.12834

Sheng, B., Song, Y., Liu, Y., Jiang, C., & Zhu, X. (2020). Association between vitamin D and uterine fibroids: A study protocol of an open label, randomised controlled trial. *BMJ Open*, *10*(11), e038709. http://dx.doi.org/10.1136/bmjopen-2020-038709

Skinner, H. C. W. (2005). Biominerals. *Mineralogical Magazine*, 69(5), 621-641. https://doi.org/10.1180/0026461056950275

Szydłowska, I., Nawrocka-Rutkowska, J., Brodowska, A., Marciniak, A., Starczewski, A., & Szczuko, M. (2022). Dietary natural compounds and vitamins as potential cofactors in uterine fibroids growth and development. *Nutrients*, *14*(4), 734. https://doi.org/10.3390/nu14040734

Truong, N. U., Edwardes, M. D. D., Papavasiliou, V., Goltzman, D., & Kremer, R. (2003). Parathyroid hormone–related peptide and survival of patients with cancer and hypercalcemia. *The American Journal of Medicine*, 115(2), 115-121. https://doi.org/10.1016/S0002-9343(03)00310-3

Turocy, J., & Williams, Z. (2022). 16 - Early and recurrent pregnancy loss: Etiology, Diagnosis, Treatment (D. M. Gershenson, G. M. Lentz, F. A. Valea, & R. A. B. T.-C. G. (Eighth E. Lobo (eds.); pp. 323-341.e3). Elsevier. https://doi.org/https://doi.org/10.1016/B978-0-323-65399-2.00025-5

Williams, G. H. (2005). Aldosterone biosynthesis, regulation, and classical mechanism of action. *Heart Failure Reviews*, *10*(1), 7-13. https://link.springer.com/article/10.1007/s10741-005-2343-3

Yafang, T., & Nadarajah, R. (2022). Challenges in the diagnosis and treatment of extrauterine leiomyomas: case series. *International Journal of Reproduction, Contraception, Obstetrics and Gynecology*, 11(1), 232-237. http://www.ijrcog.org/index.php

Yang, Q., Ciebiera, M., Bariani, M. V., Ali, M., Elkafas, H., Boyer, T. G., & Al-Hendy, A. (2022). Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. *Endocrine Reviews*, 43(4), 678-719. https://doi.org/10.1210/endrev/bnab039

Yoo, H. C., Yu, Y. C., Sung, Y., & Han, J. M. (2020). Glutamine reliance in cell metabolism. *Experimental & Molecular Medicine*, *52*(9), 1496–1516. https://doi.org/10.1038/s12276-020-00504-8

Zakeri, Z., Quaglino, D., & Ahuja, H. S. (1994). Apoptotic cell death in the mouse limb and its suppression in the hammertoe mutant. *Developmental Biology*, *165*(1), 294-297. https://doi.org/10.1006/dbio.1994.1255